Navigation Links
Study shows continued success for new HPV vaccine against virus responsible for cervical cancer

A new vaccine aimed at preventing cervical cancer is nearly 100 percent effective against the two types of the human papillomavirus (HPV) responsible for most cases of cervical cancer. Results of a nationwide study of the vaccine will be published in the May 9 issue of the New England Journal of Medicine.

Cervical cancer is the second most common cause of cancer deaths in women worldwide, resulting in nearly half a million diagnoses and 240,000 deaths each year. Every day in the United States ten women die from cervical cancer, according to Kevin Ault MD, associate professor of obstetrics and gynecology at Emory University School of Medicine, and one of the study authors.

But for the next generation of young women, a series of three shots of a new HPV vaccine marketed by Merck under the name Gardasil could make the difference in preventing cervical cancer. The vaccine targets HPV types 16 and 18, which cause about 70 percent of all cases of cervical cancer. It also targets HPV types 6 and 11, which together cause about 90 percent of all cases of genital warts.

Researchers at more than a dozen international medical centers evaluated the efficacy of quadrivalent vaccine targeting HPV types 6, 11, 16, 18 in more than 12,000 women ages 15 to 26 in 13 countries for nearly three years. They found a near 100 percent efficacy rate in prevention of HPV types 16 and 18.

"It's the first vaccine designed specifically to prevent cancer," says Dr. Ault, one of the authors of the study and a key researcher in the development of the vaccine. "The two main things to emphasize are the vaccine efficacy and the safety. These clinical trials have consistent efficacy around 98 percent. And severe reactions to the vaccine appear to be rare.

According to estimates from the Centers for Disease Control and Prevention (CDC) more than 20 million men and women in the US are infected with HPV, and more than six million new infections are reported each year, making it the most common sexually transmitted disease in the nation.

"Nearly all sexually active people are going to get exposed to the virus sometime during their lives," says Dr. Ault. "For most people, HPV causes no complications and goes away on its own. However, in some cases, if left untreated, certain high-risk types of HPV can lead to cervical cancer.

"The goal of the study was to see if we could prevent precancerous cases and we were 98 percent effective. Everyone who gets cancer goes through a pre-cancerous stage," says Ault. "There are about 50 to 60 million pap smears performed each year in the US, and about seven percent are abnormal. We spend about 3 billion dollars each year to find and treat these pre-cancerous stages caused by some type of HPV."

To date there is no vaccine specifically designed to treat disease that is already established. Dr. Ault explains the current HPV vaccine is meant to be a preventive or prophylactic vaccine Ð that's why it is given to adolescents.

Gardasil was approved by the U.S. Food and Drug Administration last year for use in females 9 to 26 years of age. While controversy has been raised about giving pre-adolescent girls a vaccine for a sexually transmitted disease, Dr. Ault argues, "young women, young girls make very good immune responses to this vaccine, so that will enhance their protection."

Researchers believe the vaccine will be effective in lowering a girl's lifetime risk of cervical cancer. To that end Merck launched the national "One Less" campaign last year, which encourages females eligible for the vaccine to begin their vaccination series of three shots over six months and to continue seeing their doctor for regular checkups and screenings.


'"/>

Source:Emory University


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/13/2016)... 2016 --> ... market report titled - Biometric Sensors Market - Global Industry ... 2023. According to the report, the global biometric sensors market was valued ... reach US$1,625.8 mn by 2023, expanding at a CAGR ... volume, the biometric sensors market is expected to reach ...
(Date:1/11/2016)... JOSE, Calif. , Jan. 11, 2016 ... of human interface solutions, today announced that its ClearPad ... driver integration (TDDI) products won two separate categories in ... Best Mobile Innovator and Best Technology Breakthrough. The Synaptics ... system cost, a simplified supply chain, thinner devices, brighter ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. 8, ... of innovative sensor-based diagnostic products, today announced the closing of ... and existing investors.  Proceeds from the financing will be used ... a hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  BioElectronics Corporation (OTC ... devices, announced today that it is responding to ... from the Securities and Exchange Commission posted on ... , Chairman of the Board of BioElectronics Corporation ... Business Administration at The Fuqua School of Business, ...
(Date:2/8/2016)... ... February 08, 2016 , ... Bulk ... loose, bulk foods at various stages of the production process. Despite frequently inspecting ... large bulk products post packaging such as sacks of dry powders. , Mettler-Toledo ...
(Date:2/8/2016)... (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, ... present information about the company,s programs at the BIOCEO conference today ... City . --> --> ... Registered attendees can request a one on one meeting through the conference ... --> New York City . --> ...
(Date:2/8/2016)... (NYSE: DPLO) announced today that its new website has gone live. On Thursday, Feb. 4, the ... Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create a smarter, more ...
Breaking Biology Technology: